Genprex, Inc. operates as a clinical-stage gene therapy company. It engages in developing a new approach for treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells, and modulates the immune response against cancer cells. Genprex, Inc. was founded in 2009 and is headquartered in Austin, Texas.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone512-537-7997
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date3/26/2019 (Estimated)
OptionableNot Optionable
Genprex (NASDAQ:GNPX) Frequently Asked Questions
What is Genprex's stock symbol?
Genprex trades on the NASDAQ under the ticker symbol "GNPX."
How were Genprex's earnings last quarter?
Genprex Inc (NASDAQ:GNPX) released its quarterly earnings data on Tuesday, November, 20th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.02. View Genprex's Earnings History.
When is Genprex's next earnings date?
What price target have analysts set for GNPX?
1 brokerages have issued 12 month target prices for Genprex's stock. Their forecasts range from $3.00 to $3.00. On average, they anticipate Genprex's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 63.9% from the stock's current price. View Analyst Price Targets for Genprex.
What is the consensus analysts' recommendation for Genprex?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genprex in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Genprex.
Has Genprex been receiving favorable news coverage?
News articles about GNPX stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Genprex earned a media sentiment score of 1.3 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the company's share price in the next several days.
Who are some of Genprex's key competitors?
Some companies that are related to Genprex include DURECT (DRRX), Imprimis Pharmaceuticals (IMMY), OASMIA PHARMACE/ADR (OASM), Catalyst Biosciences (CBIO), Zafgen (ZFGN), Fortress Biotech (FBIO), Mustang Bio (MBIO), Adamis Pharmaceuticals (ADMP), Checkpoint Therapeutics (CKPT), Chimerix (CMRX), Evofem Biosciences (EVFM), Zynerba Pharmaceuticals (ZYNE), Chembio Diagnostics (CEMI), Vernalis (VNLPY) and Merrimack Pharmaceuticals (MACK).
What other stocks do shareholders of Genprex own?
Who are Genprex's key executives?
Genprex's management team includes the folowing people:
- Mr. John Rodney Varner, Co-Founder, CEO, Sec. & Chairman (Age 62)
- Dr. Julien L. Pham M.P.H., M.D., MPH, Pres & COO (Age 42)
- Mr. Ryan M. Confer, Chief Financial Officer (Age 37)
- Dr. Jack A. Roth FACS, M.D., Chairman of Scientific & Medical Advisory Board
Who are Genprex's major shareholders?
Genprex's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Intl Fcstone Inc. (0.23%). Company insiders that own Genprex stock include Jack A Roth, John Rodney Varner and Julien L Pham. View Institutional Ownership Trends for Genprex.
Which major investors are buying Genprex stock?
GNPX stock was bought by a variety of institutional investors in the last quarter, including Intl Fcstone Inc.. Company insiders that have bought Genprex stock in the last two years include Jack A Roth, John Rodney Varner and Julien L Pham. View Insider Buying and Selling for Genprex.
How do I buy shares of Genprex?
Shares of GNPX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Genprex's stock price today?
One share of GNPX stock can currently be purchased for approximately $1.83.
How big of a company is Genprex?
Genprex has a market capitalization of $27.58 million.
What is Genprex's official website?
How can I contact Genprex?
Genprex's mailing address is 1701 Trinity Street Suite 3.322, AUSTIN TX, 78712. The company can be reached via phone at 512-537-7997 or via email at [email protected]
MarketBeat Community Rating for Genprex (NASDAQ GNPX)
MarketBeat's community ratings are surveys of what our community members think about Genprex and other stocks. Vote "Outperform" if you believe GNPX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNPX will underperform the S&P 500 over the long term. You may vote once every thirty days.
